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Abstract 
A number of Y-type push-pull compounds based on the [1,2,4]triazolo[1,5-a]pyrimidine core, namely 5,7-
di(het)aryl-substituted 2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidines, were obtained by transition metal free 
nucleophilic C–H functionalization. Substituents at both the C-5 and C-7 positions were introduced by 
successive treatment of the starting 6-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine with Grignard 
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Introduction 
 
Over the past few decades pyrimidine-cored compounds have gained considerable attention due to their 
promising application in designing different types of organic electronic devices.1 For instance, pyrimidine-
based π-conjugated compounds are widely and successfully used as active layers of thin-film (opto)electronic 
devices, including polymer solar cells,2,3 different types of OLEDs (e.g., compounds 14 and 25),4–9 or even 




Figure 1. Pyrimidine-based (opto)electronic materials. 
 
Such popularity of pyrimidines is explained by their highly π-deficient nature and ability to be an electron 
acceptor in various push-pull scaffolds providing an internal charge transfer upon excitation, and, therefore, 
inducing luminescence properties.1 In this context, the electron-deficient system of the pyrimidine derivative 
[1,2,4]triazolo[1,5-a]pyrimidine (TAP) can also be of interest for the elaboration of donor-acceptor molecules. 
Indeed, substituted TAPs show good fluorescence features, especially in the blue region of spectra.11 Since 
there is still a great demand for blue emitting materials with high efficiency, 12,13 TAPs seem to be an attractive 
object for the further research.  
One of the main routes to substituted pyrimidines is the direct C-H functionalization,1,14 otherwise known 
as nucleophilic aromatic substitution of hydrogen (SN
H).15,16 This approach can also be applied to the TAP-
system, as already demonstrated by Jie Wu and colleagues who synthesized 2,7-diaryl-substituted TAPs using 
direct copper-catalyzed CH functionalization.17 However, in general, SN
H method requires the pre-
functionalization of substrates with auxiliary groups, e.g. halogens, and the catalysis by expensive transition 
metals, which does not satisfy the atom-economy principle in terms of green chemistry and increases the 
process cost. As such, we have attempted to improve the C-H functionalization approach to substituted TAPs 
using organomagnesium compounds as nucleophilic species, thus avoiding the above-mentioned 
disadvantages and obtaining 5,7-di(het)aryl-substituted TAPs with promising luminescence features.11 
Continuing our previous work11 on the functionalization of TAPs by Grignard reagents, we present below 
the synthesis and study of more π-extended 2,5,7-tri(het)aryl-substituted TAPs, obtained with the aim of 
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Results and Discussion 
 
Synthesis of TAP compounds 
As previously highlighted, TAPs have electron deficient character, so they tend to enter into addition reactions 
with nucleophiles. Previously, we reported that the reaction of 6-bromo-TAP 4 with (het)aryl magnesium 
bromides proceeds regioselectively at the C-7 position. The resulting σH-adducts can undergo an eliminative 
aromatization, thus giving 7-substituted TAPs 5a-d, which can be further treated with additional Grignard 




Scheme 1. General pathway to 5,7-disubstituted TAPs. 
 
In accordance with our approach, we tried to construct 2,5,7-tris(het)aryl-TAPs by attacking the C-2 
position of 5,7-di(het)aryl-TAP with Grignard reagents as well as stronger nucleophiles - aryllithium 
compounds, but in both cases the attempts failed (Scheme 2). Thus, we decided to synthesize the desired 
2,5,7-tri(het)aryl-TAPs by the successive functionalization of 2-aryl-substituted TAP at its C-5 and C-7 positions 




Scheme 2. Interaction 5,7-di(het)aryl-TAPs with aryl lithium reagents. 
 
To this end, 2-phenyl-TAP 8, formed from 3-phenyl-1,2,4-triazol-5-amine (7), obtained by earlier reported 
procedure,18 and 1,1,3,3-tetramethoxypropane, was selected as a model compound to realize our strategy and 
treated with Grignard reagents prepared in situ from the corresponding aryl bromides and magnesium in THF. 
However, in the course of this reaction the regioselectivity was not observed, thus giving the mixture of 
products of the C-5 and C-7 addition. Thus, we turned our attention to another TAP derivative, namely 6-
bromo-2-phenyl-TAP 9. Substrate 9 was prepared by the condensation of 3-phenyl-1,2,4-triazol-5-amine (7) 
with 2-bromomalonaldehyde in glacial acetic acid solution (Scheme 3) in 87% yield. Compound 9 can also be 
obtained by the direct bromination of 2-phenyl-TAP 8 but only in 44% yield. 
Arkivoc 2020, vi, 330-343   Rasputin, N. A. et al. 
 
 Page 333  ©AUTHOR(S) 
 
 
Scheme 3. Preparation route of 6-bromo-2-phenyl-TAP 9. 
 
The first addition of (het)aryl magnesium bromides to compound 9 proceeded regioselectively at low 
temperatures and afforded σH-adducts 10a-d in 68-91% yields. The latter adducts were aromatized by 
dehydrobromination with triethylamine, resulting in 2,7-disubstituted TAPs 11a-d (Table 1). 
 
Table 1. Scope and yields of 2,7-disubstituted TAPs 
 
 
R1 Entry Yield (%) Entry Yield (%) 
Ph 10a 91 11a 88 
4-MeOC6H4 10b 68 11b 85 
Thien-2-yl 10c 71 11c 91 
4-Me2NC6H4 10d 85 11d 92 
 
The second attachment of Grignard reagents to derivatives 11a-d led to the formation of 2,5,7-
trisubstituted TAPs 12aa-dd after the one-pot oxidation of addition intermediates (Table 2), which, however, 
proceeded slowly and required prolonged bubbling of oxygen through the reaction mixture. 
It is worth noting that the synthesized compounds, due to the presence of an additional phenyl group in 
the azole moiety, have poorer solubility compared to the substances described in our previous article. 
However, this did not prevent us to obtain analytically pure forms of these compounds in the all cases. 
Nevertheless, it is clear, that to construct similar TAP molecules with bulk (hetero)aromatic moieties, 
fragments bearing long-chain or branched alkyl or alkoxy groups should be inserted to improve solubility of 
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Table 2. Scope and yields of 2,5,7-trisubstituted TAPs 12 
 
 
Entry R2 Com-d Yield (%) 
11a 
Ph 12aa 63 
4-MeOC6H4 12ab 53 
Thien-2-yl 12ac 83 
4-Me2NC6H4 12ad 64 
11b 
Ph 12ba 58 
4-MeOC6H4 12bb 55 
Thien-2-yl 12bc 64 
4-Me2NC6H4 12bd 60 
11c 
Ph 12ca 76 
4-MeOC6H4 12cb 61 
Thien-2-yl 12cc 57 
4-Me2NC6H4 12cd 58 
11d 
Ph 12da 54 
4-MeOC6H4 12db 52 
Thien-2-yl 12dc 53 
4-Me2NC6H4 12dd 56 
 
 
Optical and electrochemical measurements 
The UV-vis absorption and photoluminescence spectra of compounds 11 and 12 were recorded in CH2Cl2 
solution (2 × 10−5 mol ∙ L−1) at ambient temperature (Table 3). EHOMO/LUMO values were estimated from the 
corresponding onset potentials in electrochemical studies, Egap =  ELUMO −  EHOMO  (for additional data see 
SI). Measurements of Eg
opt
 were carried out by the optical method19 in a solid form. The quantum yields were 
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Table 3. The maxima of absorption, excitation and emission spectra, energy gaps and quantum yields of 
compounds 11 and 12 
Entry absλmax (nm) 
emλmax (nm) ELUMO, eV EHOMO, eV Egap Eg
opt
, eV Φ (%) 
11a 309 391 -3.01 -6.66 3.65 3.36 13 
11b 317 395 -2.95 -6.41 3.46 3.19 62 
11c 330 395 -3.28 -6.28 3.00 3.06 45 
11d 390 475 -3.29 -5.49 2.20 2.69 61 
12aa 330 400 -3.26 -6.38 3.12 3.22 29 
12ab 344 436 -3.01 -6.32 3.31 3.01 48 
12ac 351 425 -3.12 -6.30 3.18 3.01 30 
12ad 310 400 -3.01 -5.45 2.44 2.53 7 
12ba 334 408 -2.99 -6.34 3.35 3.17 53 
12bb 344 430 -2.94 -6.25 3.31 3.06 62 
12bc 350 418 -2.97 -6.31 3.34 2.97 35 
12bd 336 416 -2.90 -5.44 2.54 2.57 17 
12ca 348 407 -3.12 -6.34 3.22 3.01 24 
12cb 351 446 -3.10 -5.49 2.39 2.89 45 
12cc 355 430 -3.35 -6.20a 2.85b 2.85 31 
12cd 342 402 -3.09 -5.46 2.37 2.38 12 
12da 402 518 -2.93 -5.62 2.69 2.53 29 
12db 400 497 -2.76 -5.61 2.85 2.33 41 
12dc 359 530 -3.00 -5.56 2.56 2.52 24 
12dd 406 538 -2.76 -5.40 2.64 2.53 15 
a Calculated by equation: EHOMO = ELUMO − Eg
opt
. It was not possible to determine the oxidation 
peak. Probably, it coincides with the oxidation potential of the supporting electrolyte salt; 




All obtained substituted TAPs exhibit a very strong light absorption in violet and near UV regions of the 
spectrum (Figure 4). The luminescence of compounds 11 and 12 varies from near UV (11a-c) and violet (12aa-
12cd) to blue (11d) and green (12da, 12dc, 12dd). Compound 11a with the simplest structure has a minimum 
quantum yield among the studied 2,7-disubstituted TAPs. Replacement of the C-7 phenyl group by 4-
methoxyphenyl or 4-(N,N-dimethylamino)phenyl groups leads to significant increase in quantum yields to 
above 60%. All TAPs containing 2-thienyl-group show average quantum yields with maximum value of 45% for 
11c and 12cb. TAPs 11b and 12bb containing 4-methoxyphenyl group show significant quantum yields of 62%. 
At the same time, there is a small bathochromic and significant bathofluoric shift. 
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Figure 1. UV-vis absorption (left) and emission (right) spectra of some 2,5,7-tri(het)aryl TAPs in CH2Cl2 after 
normalization. Intensity of emission spectra is based on relative quantum yields. 
 
The greatest bathofluoric effect is achieved by introducing 4-(N,N-dimethylamino)phenyl at C-5 and C-7 
positions (compound 12dd). The emission maximum shifts to 538 nm (Figure 4). A similar effect can be 
achieved by replacing the substituent at C-5 position on thienyl as in 12dc (emission maximum at 530 nm). At 
the same time, quantum yields of these compounds are relatively low, 15 and 24%, respectively. Compound 
12db, containing 4-methoxyphenyl and 4-(N,N-dimethylamino)phenyl substituents, shows good quantum 
yield, which is higher than the group average (41%), as well as strong bathofluoric shift with emission 
maximum at 497 nm. The swap of substituents in compound 12db gives compound 12bd with an almost 
minimum quantum yield in the group (17%) and an insignificant bathofluoric shift (emission maximum at 416 
nm). 
Comparing the series of compounds 11 and 12 with the previous one of compounds 6,11 it should be noted 
that entering additional phenyl at C-2 position of TAP led to some increase in quantum yields, however, the 
luminescence maxima are on average shifted to the region of shorter wavelengths. If comparing 5-phenyl-7-
(het)aryl- and 2-phenyl-7-(het)aryl TAPs, a significant increase of quantum yields is observed, in the case of 5-









An effective route to obtain 2,7-di(het)aryl- and 2,5,7-tri(het)aryl-substituted [1,2,4]triazolo[1,5-a]pyrimidines 
based on the nucleophilic aromatic substitution of hydrogen (SN
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been developed. Successive nucleophilic addition of Grignard reagents on 6-bromo-2-phenyl-TAP enables 
substitution first at C-7 and then at C-5 via direct C-H functionalization. Basic optical and electrochemical 
properties of 2,7-di(het)aryl- and 2,5,7-tri(het)aryl-substituted derivatives have been also investigated. Most 





General. All reagents, except for 3-phenyl-1,2,4-triazol-5-amine, and solvents were purchased from 
commercial sources and dried by using standard procedures before use. 3-Phenyl-1,2,4-triazol-5-amine was 
prepared according to the literature.11 Analytical studies were carried out using equipment of the Center for 
Joint Use “Spectroscopy and Analysis of Organic Compounds” at the Postovsky Institute of Organic Synthesis 
of the Russian Academy of Sciences (Ural Division). Melting points were determined on Boetius combined 
heating stages and are uncorrected. Elemental analysis was carried on a Eurovector EA 3000 automated 
analyzer. 1H and 13C NMR spectra were recorded on AVANCE-400 and AVANCE-500 instruments in DMSO-d6 or 
CDCl3 with TMS as an internal standard. The GC-MS analysis of all samples was carried out using an Agilent GC 
7890A MS 5975C Inert XL EI/CI GC-MS spectrometer with a quadrupole mass-spectrometric detector with 
electron ionization (70 eV), and scan over the total ionic current in the range m/z 20-1000 and a quartz 
capillary column HP-5MS (30 m × 0.25 mm, film thickness 0.25 mm). Column chromatography was carried out 
using Alfa Aesar silica gel 0.040–0.063 mm (230–400 mesh), eluting with ethyl acetate/hexane (50:50) or ethyl 
acetate containing 0.5% of triethylamine. The progress of the reactions and the purity of compounds were 
checked by TLC on Sorbfil plates (Russia), in which the spots were visualized with UV light (λ 254 or 365 nm).  
Optical spectra were obtained using a Shimadzu UV-2600 double-beam UV-vis spectrophotometer, a Varian 
Cary Eclipse fluorescence spectrophotometer and a Hêllma QS-101 high precision quartz cell in CH2Cl2 
solution. Solutions of compounds with 4-(N,N-dimethylaminophenyl) substituents were made with the 
addition of Me4NOH base. Bi-quinine sulfate was used as the standard for relative quantum yield measuring. 
Cyclic voltammetry was carried out on a Metrohm Autolab PGSTAT128N potentiostat with a standard three-
electrode configuration. Typically, a three electrodes cell equipped with a glass carbon working electrode, a 
Ag/AgNO3 (0.01 M) reference electrode, and a glass carbon rod counter electrode was employed. The 
measurements were done in dichloromethane with tetrabutylammonium hexafluorophosphate (0.1 M) as the 
supporting electrolyte under an argon atmosphere at a scan rate of 100 mV/s. The potential of Ag/AgNO3 
reference electrode was calibrated by using the ferrocene/ferrocenium redox couple (Fc/Fc+). 
 
2-Phenyl[1,2,4]triazolo[1,5-a]pyrimidine (8). To solution of 3-amino-5-phenyl[1,2,4]triazole (7) (16 g, 0.1 mol) 
in glacial acid (200 mL) was added 1,1,3,3-tetramethoxypropane (16.45 mL, 0.1 mol) and water (5 mL). After 
stirring for 30 min, the mixture was heated to boiling and refluxed for 4 h. All volatiles were then removed 
under reduce pressure. To the residue was added 2-PrOH (200 mL) and the mixture was boiled, then cooled. 
The formed precipitate was filtered off and dried in air to give the title compound 8 (15.2 g, 77%), as colorless 
crystals mp 184-185 °C (2-PrOH); 1H NMR (500 MHz, DMSO-d6) δH 9.45 (dd, J 6.8, 1.9 Hz, 1H), 8.89 (dd, J 4.3, 
1.9 Hz, 1H), 8.28–8.20 (m, 2H), 7.62–7.52 (m, 3H), 7.38 (dd, J 6.8, 4.3 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δC 
164.5, 155.52, 155.47, 137.2, 130.7, 130.2, 129.0, 126.9, 110.9. Anal. Calcd. for C11H8N4: C: 67.34; H: 4.11; N: 
28.55. Found C: 67.41; H: 4.08; N: 28.51. 
5-Bromo-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (9) (Route A). To stirred solution of 2-phenyl-
[1,2,4]triazolo[1,5-a]pyrimidine (8) (1.5 g, 0.01 mol) in glacial acid (30 mL) dropwise was added a solution of 
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bromine (1.9 g, 0.012 mol) in glacial acid (20 mL). After adding bromine solution, reaction mixture was set 
aside for 2 h. To this mixture was added water (200 mL), and the crude residue was filtered off, boiled with 2-
PrOH (50 mL) and cooled. The formed precipitate was filtered off and dried in air to give the title compound 9 
(1.2 g, 44%) as colorless crystals mp 151-153 °C (2-PrOH). 1H NMR (400 MHz, DMSO-d6) δH 9.92 (d, J 2.4 Hz, 
1H), 8.98 (d, J 2.4 Hz, 1H), 8.27–8.17 (m, 2H), 7.63–7.48 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δC 165.0, 155.9, 
154.2, 137.4, 130.9, 129.9, 129.0, 126.9, 105.7. Anal. Calcd. for C11H7BrN4: C: 48.02; H: 2.56; Br: 29.04: N: 
20.37. Found C: 48.09; H: 2.60; Br: 29.11: N: 20.31. 
5-Bromo-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (9) (Route B). To stirred solution of 3-amino-5-phenyl-
[1,2,4]triazole (7) (16 g, 0.1 mol) in glacial acid (200 mL) was added 2-bromomalonaldehyde (15.1 g, 0.1 mol). 
After stirring for 30 min, the mixture was heated to boiling and refluxed for 4 h. All volatiles were removed 
under reduce pressure. The crude residue was poured onto 2-PrOH (200 mL) and boiled, then cooled. The 
precipitate filtered off and dried in air to give the title compound 9 (23.9 g, 87%), identical to that described 
above. 
 
6-Bromo-2-phenyl-7-substituted-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidines (10a-d) (General procedure). 
Magnesium powder (36 mg, 1.5 mmol) was immersed in abs. THF (10 mL) under argon or nitrogen, and the 
appropriate bromo(het)arene (1.5 mmol) was added. The reaction mixture was stirred at room temperature 
until the formation of a clear solution, cooled to -78 °C and charged with 6-bromo-2-phenyl[1,2,4]triazolo[1,5-
a]pyrimidine (4) (200 mg, 1 mmol). After 1 h the bath temperature was elevated to 50 °C. Two hours later the 
flask was cooled, and to the reaction mixture was added cold water (3 mL) and ammonium chloride (107 mg, 2 
mmol). After that, the solvent was distilled off in vacuo, the precipitate was filtered off, washed with water 
and ethyl acetate, dried and recrystallized to give compounds 10a-d. 
6-Bromo-2,7-diphenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine (10a). Pale crystals: (321 mg, 91%), mp 
182-184 °C (2-PrOH); 1H NMR (400 MHz, DMSO-d6) δH 10.29 (d, J 5.1 Hz, 1H), 7.89–7.78 (m, 2H), 7.46–7.35 (m, 
5H), 7.36–7.28 (m, 3H), 7.01 (dd, J 5.1, 0.8 Hz, 1H), 6.21 (d, J 0.8 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δC 
158.9, 148.3, 139.3, 130.8, 129.1, 129.0, 128.6, 128.5, 127.6, 125.5, 125.5, 92.6, 65.0. Anal. Calcd. for 
C17H13BrN4: C: 57.81; H: 3.71; Br: 22.62: N: 15.86. Found C: 57.84; H: 3.67; Br: 22.59: N: 15.81. 
6-Bromo-7-(4-methoxyphenyl)-2-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine (10b). Colorless 
crystals: (260 mg, 68%), mp 184-186 °C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 10.24 (d, J 4.9 Hz, 1H), 7.86–
7.80 (m, 2H), 7.43–7.32 (m, 3H), 7.28–7.22 (m, 2H), 6.99 (d, J 4.2 Hz, 1H), 6.97–6.91 (m, 2H), 6.15 (s, 1H), 3.74 
(s, 3H). 13C NMR (126 MHz, DMSO-d6) δC 159.4, 158.8, 148.1, 131.4, 130.8, 129.0, 128.9, 128.5, 125.5, 125.4, 
113.9, 93.0, 64.5, 55.1. Anal. Calcd. for C18H15BrN4O: C: 56.41; H: 3.95; Br: 20.85: N: 14.62. Found C: 57.44; H: 
3.88; Br: 20.89: N: 14.61. 
6-Bromo-7-(thiophen-2-yl)-2-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine (10c). Pale crystals: (255 
mg, 71%), mp 204-206 °C (2-PrOH); 1H NMR (400 MHz, DMSO-d6) δH 10.37 (d, J 5.1 Hz, 1H), 7.90–7.82 (m, 2H), 
7.55 (ddd, J 5.1, 1.3, 0.7 Hz, 1H), 7.48–7.33 (m, 3H), 7.26 (ddd, J 3.5, 1.3, 0.5 Hz, 1H), 7.06–6.99 (m, 2H), 6.59 
(q, J 0.7 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δC 159.0, 147.8, 142.9, 130.7, 129.1, 128.6, 127.9, 127.3, 126.8, 
125.8, 125.5, 92.1, 60.2. Anal. Calcd. for C15H11BrN4S: C: 50.15; H: 3.09; Br: 22.24; N: 15.60; S: 8.92. Found C: 
50.14; H: 3.06; Br: 22.20; N: 15.64; S: 8.95. 
6-Bromo-7-(4-(N,N-dimethylaminophenyl))-2-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine (10d). 
Light yellow crystals: (337 mg, 85%), mp 202-204 °C (MeCN); 1H NMR (400 MHz, DMSO-d6) δH 10.17 (d, J 5.0 
Hz, 1H), 7.87–7.79 (m, 2H), 7.43–7.31 (m, 3H), 7.16–7.08 (m, 2H), 6.96 (dd, J 5.0, 0.8 Hz, 1H), 6.73–6.65 (m, 
2H), 6.04 (d, J 0.7 Hz, 1H), 2.88 (s, 6H). 13C NMR (126 MHz, DMSO-d6) δC 158.7, 150.4, 148.1, 130.9, 128.9, 
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128.5, 128.3, 126.5, 125.5, 125.1, 112.0, 93.5, 64.8, 40.0. Anal. Calcd. for C19H18BrN5: C: 57.59; H: 4.58; Br: 
20.16; N: 17.67. Found C: 57.64; H: 4.60; Br: 20.19; N: 17.61. 
 
2,7-Disubstituted [1,2,4]triazolo[1,5-a]pyrimidines (11a-d) (General procedure). The relevant 6-bromo-7-
substituted-2-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine 5a-d (1 mmol) and triethylamine (TEA) 
(0.216 mL, 1.5 mmol) were added to acetonitrile (10 mL) and heated at reflux until the initial substance 
completely disappeared (by TLC). The reaction mixture was then diluted with water (5 ml), cooled, then the 
precipitate was filtered, washed with water, dried and recrystallized to afford the desired products 11a-d. 
2,7-Diphenyl[1,2,4]triazolo[1,5-a]pyrimidine (11a). Colorless needles: (240 mg, 88%), mp 170-171 °C (2-
PrOH); 1H NMR (400 MHz, DMSO-d6) δH 8.93 (d, J 4.7 Hz, 1H), 8.33–8.27 (m, 2H), 8.27–8.22 (m, 2H), 7.73–7.67 
(m, 3H), 7.62 (d, J 4.7 Hz, 1H), 7.60–7.54 (m, 3H). 13C NMR (126 MHz, DMSO-d6) δC 164.2, 156.7, 154.9, 147.0, 
131.7, 130.6, 130.3, 129.7, 129.6, 128.9, 128.7, 126.9, 109.7. Anal. Calcd. for C17H12N4: C: 74.98; H: 4.44; N: 
20.58. Found C: 75.07; H: 4.39; N: 20.52. 
7-(4-Methoxyphenyl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (11b). Pale powder: (257 mg, 85%), mp 167-
169 °C (2-PrOH); 1H NMR (500 MHz, DMSO-d6) δH 8.87 (d, J 4.8 Hz, 1H), 8.42–8.36 (m, 2H), 8.29–8.23 (m, 2H), 
7.61 (d, J 4.8 Hz, 1H), 7.60–7.54 (m, 3H), 7.28–7.21 (m, 2H), 3.91 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δC 
164.0, 162.0, 156.8, 154.6, 146.6, 131.5, 130.6, 130.4, 128.9, 126.9, 121.6, 114.2, 108.5, 55.5. Anal. Calcd. for 
C18H14N4O: C: 71.51; H: 4.67; N: 18.53. Found C: 71.54; H: 4.70; N: 18.57. 
2-Phenyl-7-(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (11c). Light brown powder: (253 mg, 91%), mp 198-
200 °C (2-PrOH); 1H NMR (400 MHz, DMSO-d6) δH 8.87 (d, J 5.0 Hz, 1H), 8.65 (dd, J 4.0, 1.2 Hz, 1H), 8.39–8.31 
(m, 2H), 8.24 (dd, J 5.0, 1.2 Hz, 1H), 7.99 (d, J 5.0 Hz, 1H), 7.61 (qt, J 5.0, 2.0 Hz, 3H), 7.47 (dd, J 5.0, 3.9 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δC 164.0, 156.3, 154.1, 140.7, 135.6, 133.2, 130.8, 130.1, 129.9, 129.0, 128.4, 
127.0, 106.0. Anal. Calcd. for C15H10N4S: C: 64.73; H: 3.62; N: 20.13; S: 11.52. Found C: 64.79; H: 3.67; N: 20.19; 
S: 11.49. 
7-[4-(N,N-Dimethylaminophenyl)]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine 11d. Yellow needles: (290 mg, 
92%), mp 213-214 °C (2-PrOH); 1H NMR (400 MHz, DMSO-d6) δH 8.76 (d, J 5.0 Hz, 1H), 8.46–8.38 (m, 2H), 8.32–
8.24 (m, 2H), 7.63–7.51 (m, 4H), 6.98–6.90 (m, 2H), 3.09 (s, 6H). 13C NMR (126 MHz, DMSO-d6) δC 163.8, 157.1, 
154.0, 152.4, 147.0, 131.1, 130.53, 130.51, 128.9, 126.9, 115.2, 111.3, 106.7, 39.6. Anal. Calcd. for C19H17N5: C: 
72.36; H: 5.43; N: 22.21. Found C: 72.29; H: 5.47; N: 22.19. 
 
2,5,7-Trisubstituted [1,2,4]triazolo[1,5-a]pyrimidines (12aa-dd) (General procedure). Grignard reagent 
solution was prepared from magnesium powder (36 mg, 1.5 mmol) and the appropriate bromo(het)arene (1.5 
mmol) in THF (10 mL). It was cooled to -78 °C and the corresponding 7-substituted-TAP 6 (1 mmol) was added. 
After 1 h the bath temperature was elevated to 50 °C, and the reaction mixture was stirred for another 2 h. 
Then the oxygen atmosphere was created and kept for 2 h. When the reaction was completed, the flask was 
cooled, and the reaction mixture was charged with cold water (2-3 mL) and ammonium chloride (107 mg, 2 
mmol). The volatiles were then distilled off in vacuo, the residue was filtered, washed with cold water and 
hexane, dried and recrystallized to afford the desired products 12aa-dd. 
2,5,7-Triphenyl[1,2,4]triazolo[1,5-a]pyrimidine (12aa). Colorless powder: (220 mg, 63%), mp 176-178 °C (2-
PrOH); 1H NMR (500 MHz, DMSO-d6) δH 8.47–8.42 (m, 2H), 8.42–8.37 (m, 2H), 8.29–8.23 (m, 2H), 8.17 (s, 1H), 
7.75–7.67 (m, 3H), 7.65–7.61 (m, 3H), 7.61–7.52 (m, 3H). 13C NMR (126 MHz, CDCl3) δC 166.1, 161.0, 157.4, 
147.5, 136.5, 131.7, 131.2, 130.6, 130.5, 130.3, 129.4, 129.0, 128.9, 128.6, 127.7, 127.6, 106.1. Anal. Calcd. for 
C23H16N4: C: 79.17; H: 4.63; N: 16.08. Found C: 79.21; H: 4.67; N: 16.09. 
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5-(4-Methoxyphenyl)-2,7-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine (12ab). Colorless powder: (313 mg, 53%), 
mp 232-233 °C (MeCN); 1H NMR (400 MHz, DMSO-d6) δH 8.44–8.40 (m, 2H), 8.38–8.34 (m, 2H), 8.28–8.20 (m, 
2H), 8.10 (s, 1H), 7.74–7.66 (m, 3H), 7.62–7.51 (m, 3H), 7.20–7.12 (m, 2H), 3.89 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δC 165.7, 162.3, 160.6, 157.3, 147.2, 131.6, 130.68, 130.65, 130.4, 129.4, 129.3, 128.9, 128.8, 128.6, 
127.5, 114.4, 105.6, 55.5. Anal. Calcd. for C24H18N4O: C: 76.17; H: 4.79; N: 14.81. Found C: 76.22; H: 4.74; N: 
14.84. 
2,7-Diphenyl-5-(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (12ac). Pale powder: (294 mg, 83%), mp 191-
193 °C (2-PrOH); 1H NMR (500 MHz, DMSO-d6) δH 8.38–8.30 (m, 3H), 8.25–8.19 (m, 2H), 8.14 (s, 1H), 7.94 (dd, J 
5.0, 1.1 Hz, 1H), 7.75–7.66 (m, 3H), 7.61–7.51 (m, 3H), 7.32 (dd, J 5.0, 3.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δC 
165.9, 157.0, 156.0, 147.4, 142.4, 131.7, 131.4, 130.6, 130.5, 130.1, 129.4, 128.9, 128.6, 128.52, 128.45, 127.5, 
105.1. Anal. Calcd. for C21H14N4S: C: 71.17; H: 3.98; N: 15.81; S: 9.05. Found C: 71.19; H: 3.96; N: 15.88; S: 9.03. 
5-[4-(N,N-Dimethylaminophenyl)]-2,7-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine (12ad). Yellow powder: (250 
mg, 64%), mp 241-243 °C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 8.37–8.27 (m, 4H), 8.28–8.18 (m, 2H), 7.98 
(s, 1H), 7.72–7.65 (m, 3H), 7.60–7.50 (m, 3H), 6.90–6.83 (m, 2H), 3.06 (s, 6H). 13C NMR (126 MHz, CDCl3) δC 
165.3, 160.9, 152.4, 146.6, 131.3, 131.0, 130.8, 130.2, 129.4, 129.0, 128.9, 128.7, 128.5, 127.4, 123.5, 111.7, 
105.1, 40.1. Anal. Calcd. for C25H21N5: C: 76.70; H: 5.41; N: 17.89. Found C: 76.72; H: 5.38; N: 17.85. 
7-(4-Methoxyphenyl)-2,5-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine (12ba). Pale powder: (220 mg, 58%), mp 
207-209 °C (MeCN); 1H NMR (400 MHz, DMSO-d6) δH 8.46 (dd, J 26.0, 6.4 Hz, 4H), 8.31–8.24 (m, 2H), 8.13 (s, 
1H), 7.65–7.55 (m, 6H), 7.26 (d, J 8.5 Hz, 2H), 3.93 (s, 3H). 13C NMR (126 MHz, CDCl3) δC 165.9, 162.4, 160.8, 
157.5, 147.2, 136.7, 131.3, 131.1, 130.7, 130.4, 129.0, 128.6, 127.7, 127.5, 122.4, 114.3, 105.1, 55.6. Anal. 
Calcd. for C24H18N4O: C: 76.17; H: 4.79; N: 14.81. Found C: 76.21; H: 4.77; N: 14.79. 
5,7-Bis(4-methoxyphenyl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12bb). Pale powder: (224 mg, 55%), mp 
200-203 °C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 8.49–8.44 (m, 2H), 8.43–8.38 (m, 2H), 8.29–8.22 (m, 2H), 
8.05 (s, 1H), 7.62–7.51 (m, 3H), 7.29–7.21 (m, 2H), 7.19–7.11 (m, 2H), 3.92 (s, 3H), 3.88 (s, 3H). 13C NMR (126 
MHz, CDCl3) δC 165.6, 162.2, 162.2, 160.4, 157.5, 146.9, 131.2, 130.8, 130.3, 129.3, 129.1, 128.5, 127.5, 122.6, 
114.3, 114.2, 104.5, 55.5, 55.4. Anal. Calcd. for C20H20N4O2: C: 73.51; H: 4.94; N: 13.72. Found C: 73.57; H: 4.89; 
N: 13.79. 
7-(4-Methoxyphenyl)-2-phenyl-5-(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (12bc). Light brown powder: 
(245 mg, 64%), mp 221-223 °C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 8.47–8.38 (m, 2H), 8.35 (dd, J 3.8, 1.2 
Hz, 1H), 8.29–8.21 (m, 2H), 8.11 (s, 1H), 7.93 (dd, J 5.0, 1.1 Hz, 1H), 7.63–7.51 (m, 3H), 7.31 (dd, J 5.0, 3.7 Hz, 
1H), 7.30–7.22 (m, 2H), 3.93 (s, 3H). 13C NMR (126 MHz, CDCl3) δC 165.8, 162.4, 157.1, 155.9, 147.1, 142.5, 
131.3, 131.2, 130.7, 130.4, 128.6, 128.4, 128.3, 127.5, 122.2, 114.3, 104.1, 55.6. Anal. Calcd. for C22H16N4OS: C: 
68.73; H: 4.20; N: 14.57; S: 8.34. Found C: 68.78; H: 4.18; N: 14.60; S: 8.29. 
7-(4-Methoxyphenyl)-5-[4-(N,N-dimethylaminophenyl)]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12bd). 
Orange powder: (253 mg, 60%), mp 211-214 °C [Chromatographed with EtOAc/hexane (50:50)]; 1H NMR (400 
MHz, DMSO-d6) δH 8.45–8.38 (m, 2H), 8.33–8.20 (m, 4H), 7.94 (s, 1H), 7.62–7.49 (m, 3H), 7.27–7.20 (m, 2H), 
6.86 (d, J 9.1 Hz, 2H), 3.92 (s, 3H), 3.06 (s, 6H). 13C NMR (126 MHz, CDCl3) δC 162.2, 160.8, 151.7, 146.5, 131.3, 
131.3, 131.2, 130.4, 129.1, 128.6, 128.6, 127.5, 122.5, 114.3, 114.2, 112.5, 104.5, 55.5, 40.7. Anal. Calcd. for 
C26H23N5O: C: 74.09; H: 5.50; N: 16.62. Found C: 74.12; H: 5.53; N: 16.56. 
2,5-Diphenyl-7-(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (12ca). Pale powder: (269 mg, 76%), mp 186-
187 °C (2-PrOH); 1H NMR (500 MHz, CDCl3) δH 8.57 (dd, J 3.9, 1.2 Hz, 1H), 8.51–8.45 (m, 2H), 8.32–8.24 (m, 2H), 
7.87–7.79 (m, 2H), 7.60–7.48 (m, 6H), 7.35 (dd, J 5.0, 3.9 Hz, 1H). 13C NMR (126 MHz, CDCl3) δC 166.8–164.4 
(m), 160.7, 158.2–153.1 (m), 141.0, 136.6, 133.1, 132.6, 131.3, 131.2, 130.7, 130.5, 129.0, 128.7, 128.4, 127.7, 
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102.7, 77.2. Anal. Calcd. for C21H14N4S: C: 71.17; H: 3.98; N: 15.81; S: 9.05. Found C: 71.14; H: 4.01; N: 15.86; S: 
9.09. 
5-(4-Methoxyphenyl)-2-phenyl-7-(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (12cb). Pale powder: (234 mg, 
61%), mp 211-213 °C (MeCN); 1H NMR (400 MHz, DMSO-d6) δH 8.83 (d, J 3.9 Hz, 1H), 8.46–8.39 (m, 3H), 8.37–
8.30 (m, 2H), 8.23 (d, J 5.0 Hz, 1H), 7.65–7.56 (m, 3H), 7.52–7.45 (m, 1H), 7.20–7.13 (m, 2H), 3.89 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δC 165.7, 162.2, 160.1, 157.1, 140.7, 132.7, 132.4, 131.5, 130.7, 130.5, 129.3, 129.0, 
128.7, 128.3, 127.6, 114.3, 102.0, 55.5. Anal. Calcd. for C22H16N4OS: C: 68.73; H: 4.20; N: 14.57; S: 8.34. Found 
C: 68.65; H: 4.18; N: 14.59; S: 8.32. 
2-Phenyl-5,7-di(thien-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidine (12cc). Light brown powder: (205 mg, 57%), mp 
227-229 °C (2-PrOH); 1H NMR (400 MHz, DMSO-d6) δH 8.79 (dd, J 4.0, 1.2 Hz, 1H), 8.48 (s, 1H), 8.39 (d, J 3.8 Hz, 
1H), 8.36–8.29 (m, 2H), 8.25 (dd, J 5.1, 1.1 Hz, 1H), 7.96–7.89 (m, 1H), 7.67–7.54 (m, 3H), 7.49 (t, J 4.5 Hz, 1H), 
7.34 (dd, J 5.0, 3.7 Hz, 1H). 13C NMR (126 MHz, CDCl3) δC 156.0, 142.1, 141.0, 133.5, 133.4, 133.0, 131.6, 131.5, 
130.9, 130.76, 130.75, 129.8, 128.8, 128.6, 128.4, 127.7, 102.0. Anal. Calcd. for C19H12N5S2: C: 63.31; H: 3.36; 
N: 15.54; S: 17.79. Found C: 63.25; H: 3.38; N: 15.49; S: 17.82. 
7-(Thien-2-yl)-5-[4-(N,N-dimethylaminophenyl)]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12cd). Orange 
powder: (230 mg, 58%), mp 203-205 °C [Chromatographed with EtOAc/hexane (50:50)]; 1H NMR (500 MHz, 
DMSO-d6) δH 8.80 (dd, J 4.0, 1.2 Hz, 1H), 8.34–8.29 (m, 5H), 8.20 (dd, J 5.0, 1.1 Hz, 1H), 7.63–7.56 (m, 3H), 7.47 
(dd, J 5.1, 3.9 Hz, 1H), 6.91–6.83 (m, 2H), 3.06 (s, 6H). 13C NMR (126 MHz, CDCl3) δC 165.1, 160.5, 157.2, 152.1, 
140.1, 132.1, 132.0, 131.7, 130.8, 130.6, 130.3, 128.9, 128.7, 128.6, 128.6, 111.8, 101.6, 40.2. Anal. Calcd. for 
C23H19N5S: C: 69.50; H: 4.82; N: 17.62; S: 8.07. Found C: 69.52; H: 4.85; N: 17.68; S: 8.01. 
7-[4-(N,N-Dimethylaminophenyl)]-2,5-diphenyl[1,2,4]triazolo[1,5-a]pyrimidine (12da). Yellow needles: (211 
mg, 54%), mp 230-233 °C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 8.55–8.49 (m, 2H), 8.44–8.38 (m, 2H), 
8.32–8.26 (m, 2H), 8.06 (s, 1H), 7.65–7.52 (m, 20H), 6.98–6.93 (m, 2H), 3.10 (s, 6H). 13C NMR (126 MHz, DMSO-
d6) δC 164.3, 159.7, 157.1, 152.3, 147.2, 136.6, 131.3, 130.9, 130.6, 130.4, 128.9, 127.6, 126.9, 126.8, 115.7, 
111.2, 103.7, 39.6. Anal. Calcd. for C25H21N5: C: 76.70; H: 5.41; N: 17.89. Found C: 76.76; H: 5.47; N: 17.83. 
7-[4-(N,N-Dimethylaminophenyl)]-5-(4-methoxyphenyl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12db). 
Orange powder: (219 mg, 52%), mp 216-217°C (MeCN); 1H NMR (500 MHz, DMSO-d6) δH 8.51–8.45 (m, 2H), 
8.41–8.35 (m, 2H), 8.30–8.24 (m, 2H), 7.97 (s, 1H), 7.62–7.51 (m, 3H), 7.17–7.11 (m, 2H), 6.97–6.91 (m, 2H), 
3.88 (s, 3H), 3.09 (s, 6H). 13C NMR (126 MHz, CDCl3) δC 162.1, 160.3, 152.1, 147.3, 131.1, 131.0, 130.5, 129.3, 
129.1, 128.8, 128.6, 128.5, 127.6, 127.5, 114.2, 111.7, 103.5, 55.4, 40.3. Anal. Calcd. for C26H23N5O: C: 74.09; H: 
5.50; N: 16.62. Found C: 74.01; H: 5.56; N: 16.59. 
7-[4-(N,N-Dimethylaminophenyl)]-5-(thien-2-yl)-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12dc). Dark yellow 
powder: (210 mg, 53%), mp 261-263 °C (Chromatographed with EtOAc/hexane (50:50)); 1H NMR (500 MHz, 
DMSO-d6) δH 8.52–8.45 (m, 2H), 8.33 (dd, J 3.8, 1.1 Hz, 1H), 8.31–8.22 (m, 2H), 8.04 (s, 1H), 7.89 (dd, J 5.0, 1.1 
Hz, 1H), 7.62–7.51 (m, 7H), 7.30 (dd, J 5.0, 3.7 Hz, 1H), 6.99–6.91 (m, 2H), 3.10 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δC 165.4, 157.4, 155.5, 152.5, 147.6, 143.0, 131.0, 131.0, 130.6, 130.2, 128.5, 128.3, 127.9, 127.5, 116.5, 
111.4, 102.7, 40.0. Anal. Calcd. for C23H19N5S: C: 69.50; H: 4.82; N: 17.62; S: 8.07. Found C: 69.45; H: 4.80; N: 
17.59; S: 8.12. 
5,7-Bis[4-(N,N-dimethylaminophenyl)]-2-phenyl[1,2,4]triazolo[1,5-a]pyrimidine (12dd). Orange powder: 
(243 mg, 56%), mp 205-207 °C (Chromatographed with EtOAc/hexane (50:50)); 1H NMR (500 MHz, DMSO-d6) 
δH 8.46–8.40 (m, 2H), 8.30–8.22 (m, 4H), 7.87 (s, 1H), 7.61–7.50 (m, 3H), 6.97–6.91 (m, 2H), 6.88–6.83 (m, 2H), 
3.09 (s, 12H), 3.05 (s, 6H). 13C NMR (126 MHz, CDCl3) δC 164.8, 160.4, 157.8, 152.2, 152.1, 146.9, 131.3, 130.8, 
129.9, 128.9, 128.4, 127.4, 124.1, 117.2, 111.6, 111.3, 102.8, 40.12, 40.06. Anal. Calcd. for C27H26N6: C: 74.63; 
H: 6.03; N: 19.34. Found C: 74.54; H: 6.07; N: 19.39. 
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